Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Where Today's News Shapes Tomorrow
